Ayala Pharmaceuticals Stock Beta
| ADXSDelisted Stock | USD 1.38 0.34 32.69% |
Ayala Pharmaceuticals fundamentals help investors to digest information that contributes to Ayala Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Ayala OTC Stock. The fundamental analysis module provides a way to measure Ayala Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ayala Pharmaceuticals otc stock.
Ayala |
Ayala Pharmaceuticals OTC Stock Beta Analysis
Ayala Pharmaceuticals' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Ayala Pharmaceuticals Beta | 2.28 |
Most of Ayala Pharmaceuticals' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ayala Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
CompetitionIn accordance with the recently published financial statements, Ayala Pharmaceuticals has a Beta of 2.28. This is 165.12% higher than that of the Healthcare sector and 64.03% higher than that of the Biotechnology industry. The beta for all United States stocks is notably lower than that of the firm.
Ayala Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ayala Pharmaceuticals' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Ayala Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Ayala Pharmaceuticals by comparing valuation metrics of similar companies.Ayala Pharmaceuticals is currently under evaluation in beta category among its peers.
As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Ayala Pharmaceuticals will likely underperform.
Ayala Fundamentals
| Return On Equity | -41.98 | ||||
| Return On Asset | -24.13 | ||||
| Current Valuation | (25.1 M) | ||||
| Shares Outstanding | 145.64 M | ||||
| Shares Owned By Insiders | 0.01 % | ||||
| Shares Owned By Institutions | 0.10 % | ||||
| Number Of Shares Shorted | 39.89 K | ||||
| Price To Earning | (1.62) X | ||||
| Price To Book | 5.25 X | ||||
| Price To Sales | 990.34 X | ||||
| Revenue | 250 K | ||||
| Gross Profit | 3.24 M | ||||
| EBITDA | (15.31 M) | ||||
| Net Income | (16.24 M) | ||||
| Cash And Equivalents | 28.15 M | ||||
| Cash Per Share | 15.50 X | ||||
| Total Debt | 19 K | ||||
| Current Ratio | 15.64 X | ||||
| Book Value Per Share | 0.32 X | ||||
| Cash Flow From Operations | (16.04 M) | ||||
| Short Ratio | 0.95 X | ||||
| Earnings Per Share | (0.33) X | ||||
| Number Of Employees | 14 | ||||
| Beta | 2.28 | ||||
| Market Capitalization | 247.58 M | ||||
| Total Asset | 169.04 M | ||||
| Retained Earnings | (354.94 M) | ||||
| Working Capital | 132.17 M | ||||
| Current Asset | 159.88 M | ||||
| Current Liabilities | 27.71 M |
About Ayala Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ayala Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ayala Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ayala Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Other Consideration for investing in Ayala OTC Stock
If you are still planning to invest in Ayala Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Ayala Pharmaceuticals' history and understand the potential risks before investing.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |